Pharmaceutical Investing TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
Pharmaceutical Investing Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
Pharmaceutical Investing Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
Pharmaceutical Investing Arvinas Announces Data Presentations from the Vepdegestrant Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium
Pharmaceutical Investing U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
Pharmaceutical Investing Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
Pharmaceutical Investing Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
Pharmaceutical Investing Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
Pharmaceutical Investing Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
Pharmaceutical Investing PADCEV Plus KEYTRUDA, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
Pharmaceutical Investing TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
